企業プロフィール
AbbVie Inc 株価・ニュース・カタリスト
- ティッカー:
- ABBV
- 取引所:
- NYSE
- セクター:
- Biopharma, Immunotherapy, CNS
- 所在地:
- United States
株価パフォーマンス
250.33 USD (+0.35%)
終値
最終更新: 2026年8月17日
381B USD
時価総額
株価変動の要因
As of Aug 17, 2026, ABBV closed up 0.35% at $250.33. No new same-company headline was identified in the current news window.
企業概要
事業概要
AbbVie is a large biopharmaceutical company with major franchises in immunology, aesthetics, neuroscience, and oncology. Its identity has evolved from a single-product legacy into a broader diversified growth story.
所在地とセクター分類
Headquartered in the United States and listed on NYSE, AbbVie has a global commercial footprint with meaningful exposure to both developed and international markets. It sits firmly in large-cap biopharma.
ビジネスモデルの特徴
AbbVie combines mature cash flow with pipeline reinvestment and lifecycle management. Investors focus on immunology growth, aesthetic product performance, patent runoff, and the replacement cycle across its core portfolio.
バイオ業界での位置付け
AbbVie is a mature large-cap biotech-like pharma with a strong commercial base and ongoing catalyst sensitivity. It is not binary, but pipeline, label, and patent developments still matter for valuation.
今後のカタリスト
- AbbVie’s key near-term catalysts are pivekimab sunirine’s BLA path, Rinvoq label-expansion opportunities, and continued Skyrizi momentum. The next checkpoint matters because it tells investors whether the program is still moving on schedule or whether the timeline needs to be reset. A clean outcome also makes it easier to think about the next regulatory or label step instead of just the current filing.
最近のニュース
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。